https://www.healthheraldgrenada.com/article/906786185-molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin Health Herald Grenada en PressRelease 2026-04-19T16:00:00+00:00 Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 https://ml.globenewswire.com/media/ac0d728a-e43a-4d2b-a9c5-52e74d0dd1eb/small/molecularpartners-logo-jpg.jpg https://www.healthheraldgrenada.com/article/906641487-herz-p1-smart-oximeter-claims-evaluated-best-pulse-oxygen-monitor-device-on-the-market-with-clinical-grade-accuracy Health Herald Grenada en PressRelease 2026-04-18T23:25:01+00:00 Herz P1 Smart Oximeter Claims Evaluated: Best Pulse Oxygen Monitor Device on the Market with Clinical-Grade Accuracy https://zingfast.com/wp-content/uploads/2026/04/Herz-P1-Smart-Oximeter.jpg https://www.healthheraldgrenada.com/article/906622464-vigor-boost-gummies-claims-evaluated-the-forcevital-male-enhancement-formula-under-investigation Health Herald Grenada en PressRelease 2026-04-18T21:34:15+00:00 Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation https://zingfast.com/wp-content/uploads/2026/04/Vigor-Boost-Gummies.jpg https://www.healthheraldgrenada.com/article/906601019-slimleaf-claims-evaluated-the-fitburn-formula-using-slim-leaf-ingredients-for-weight-loss Health Herald Grenada en PressRelease 2026-04-18T20:10:35+00:00 SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss https://zingfast.com/wp-content/uploads/2026/04/SlimLeaf.jpg https://www.healthheraldgrenada.com/article/906577634-pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the Health Herald Grenada en PressRelease 2026-04-18T17:31:00+00:00 Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/e31d4c37-738e-4662-861d-675c8c564317/medium/figure-1.jpg https://www.healthheraldgrenada.com/article/906577555-theriva-biologics-anuncia-la-pr-xima-presentaci-n-de-datos-adicionales-del-ensayo-cl-nico-virage-de-fase-2b-del-vcn-01-para-el-c-ncer-de-p-ncreas Health Herald Grenada en PressRelease 2026-04-18T17:17:08+00:00 Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026 https://ml.globenewswire.com/media/ed41908b-8799-4f56-bc3c-acff4f4872eb/small/tovx-logo-jpg.jpg https://www.healthheraldgrenada.com/article/906552980-maps-welcomes-federal-action-to-advance-science-driven-psychedelic-research-and-policy Health Herald Grenada en PressRelease 2026-04-18T15:34:50+00:00 MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy https://ml.globenewswire.com/media/4f774750-4742-4818-be22-116e2b2085b1/small/maps-logo-2021-primary-horizontal-white-background-1200x486.jpg https://www.healthheraldgrenada.com/article/906501406-press-release-escmid-sanofi-s-nuvaxovid-covid-19-vaccine-showed-better-tolerability-than-mnexspike-in-head-to-head-study Health Herald Grenada en PressRelease 2026-04-18T10:00:00+00:00 Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.healthheraldgrenada.com/article/906501531-communiqu-de-presse-escmid-le-nuvaxovid-vaccin-contre-la-covid-19-de-sanofi-a-montr-une-meilleure-tol-rance-que-le-mnexspike-dans-une-tude Health Herald Grenada en PressRelease 2026-04-18T10:00:00+00:00 Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe   https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.healthheraldgrenada.com/article/906476191-vigosurge-claims-evaluated-analyzing-the-ingredients-benefits-side-effects-risk-and-customer-complaints Health Herald Grenada en PressRelease 2026-04-18T08:34:39+00:00 VigoSurge Claims Evaluated: Analyzing the Ingredients' Benefits, Side Effects Risk and Customer Complaints https://zingfast.com/wp-content/uploads/2026/04/VigoSurge.jpg https://www.healthheraldgrenada.com/article/906451168-argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broader-vyvgart-use-across-mg-and-cidp Health Herald Grenada en PressRelease 2026-04-18T05:00:00+00:00 argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP https://ml-eu.globenewswire.com/media/be37b058-e737-46dc-b05a-c2240f4da489/small/argenx-logo-default-png.png https://www.healthheraldgrenada.com/article/906425526-steel-flow-pro-claims-evaluated-analyzing-the-prostate-support-ingredients-side-effects-risk-and-hidden-complaints Health Herald Grenada en PressRelease 2026-04-18T02:49:20+00:00 Steel Flow Pro Claims Evaluated: Analyzing the Prostate Support Ingredients, Side Effects Risk and Hidden Complaints https://zingfast.com/wp-content/uploads/2026/04/Steel-Flow-Pro.jpg https://www.healthheraldgrenada.com/article/906425477-vidacalm-claims-evaluated-analyzing-the-formula-s-ingredients-side-effects-risk-and-user-complaints Health Herald Grenada en PressRelease 2026-04-18T01:30:16+00:00 VidaCalm Claims Evaluated: Analyzing the Formula's Ingredients, Side Effects Risk and User Complaints https://zingfast.com/wp-content/uploads/2026/04/VidaCalm.jpg https://www.healthheraldgrenada.com/article/906376671-iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Herald Grenada en PressRelease 2026-04-17T21:15:00+00:00 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d0986bd6-4603-4e31-8ed1-f23b3e123605/small/iovance-jpg.jpg https://www.healthheraldgrenada.com/article/906378346-keeps-hair-growth-product-claims-evaluated-topical-oral-rx-hair-loss-prescription-treatment-with-finasteride-dutasteride-minoxidil Health Herald Grenada en PressRelease 2026-04-17T21:01:05+00:00 Keeps Hair Growth Product Claims Evaluated: Topical & Oral RX Hair Loss Prescription Treatment with Finasteride, Dutasteride & Minoxidil https://zingfast.com/wp-content/uploads/2026/04/Keeps-Hair-Growth.jpg https://www.healthheraldgrenada.com/article/906378336-boundless-bio-presents-preclinical-breast-cancer-data-from-its-oral-kinesin-degrader-program-at-2026-aacr-annual-meeting Health Herald Grenada en PressRelease 2026-04-17T20:49:47+00:00 Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting https://ml.globenewswire.com/media/3b8ff619-e7af-4c58-a7f2-de0c4019068d/small/boundlessbiologo-jpg.jpg https://www.healthheraldgrenada.com/article/906376058-celularity-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing Health Herald Grenada en PressRelease 2026-04-17T20:35:00+00:00 Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing https://ml.globenewswire.com/media/ODBmYzBlZTctZGRjMC00YzIzLWEyYTEtODVjOGVkNjJlM2M4LTEyMTY1NjItMjAyNi0wNC0xNy1lbg==/tiny/Celularity-Inc-.png https://www.healthheraldgrenada.com/article/906376026-zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Herald Grenada en PressRelease 2026-04-17T20:15:00+00:00 Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/11a7c081-eaf9-4e1d-b413-227c20d8d41a/small/zenas-logo-jpg.jpg https://www.healthheraldgrenada.com/article/906375383-alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules Health Herald Grenada en PressRelease 2026-04-17T20:05:00+00:00 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules https://ml.globenewswire.com/media/0a1b4459-3df3-4c9f-ba29-ace8d7ad1b9a/small/alx-01-stacked-white-png.png https://www.healthheraldgrenada.com/article/906375426-theriva-biologics-announces-upcoming-presentation-of-additional-data-from-the-virage-phase-2b-clinical-trial-of-vcn-01-in-metastatic-pancreatic Health Herald Grenada en PressRelease 2026-04-17T20:05:00+00:00 Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting https://ml.globenewswire.com/media/ed41908b-8799-4f56-bc3c-acff4f4872eb/small/tovx-logo-jpg.jpg https://www.healthheraldgrenada.com/article/906375629-4dmt-announces-new-employment-inducement-grants Health Herald Grenada en PressRelease 2026-04-17T20:05:00+00:00 4DMT Announces New Employment Inducement Grants https://ml.globenewswire.com/media/027d40cf-145a-47b2-a0b8-823759376823/small/logo-2x-png.png https://www.healthheraldgrenada.com/article/906375662-camp4-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Herald Grenada en PressRelease 2026-04-17T20:05:00+00:00 CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/72048fc6-0a8d-4ed2-9be8-ec0ee0afd8ba/small/cmp4-21-logo-full-color-jpg.jpg https://www.healthheraldgrenada.com/article/906376371-oric-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings Health Herald Grenada en PressRelease 2026-04-17T20:05:00+00:00 ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting https://ml.globenewswire.com/media/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb/small/oric-png.png https://www.healthheraldgrenada.com/article/906376697-pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-activity-in-a-hnscc-model-with-mamicvo-in-combination-with-anti-pd-1-at Health Herald Grenada en PressRelease 2026-04-17T20:05:00+00:00 Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 https://ml.globenewswire.com/media/d3b77f06-3f52-42af-8f38-e3fda9c8025b/small/pyxis-logo-jpg.jpg https://www.healthheraldgrenada.com/article/906377182-revolution-medicines-announces-closing-of-concurrent-upsized-public-offerings-with-aggregate-gross-proceeds-of-approximately-2-2-billion-including Health Herald Grenada en PressRelease 2026-04-17T20:02:00+00:00 Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.healthheraldgrenada.com/article/906375334-adagene-presents-two-posters-at-aacr-2026-with-new-data-highlighting-muzastotug-s-potential-as-a-backbone-combination-therapy-for-multiple-tumor-types Health Herald Grenada en PressRelease 2026-04-17T20:01:00+00:00 Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://www.healthheraldgrenada.com/article/906375816-xilio-therapeutics-announces-new-preclinical-data-at-aacr-annual-meeting-for-xtx601-a-masked-t-cell-engager-targeting-cldn18-2 Health Herald Grenada en PressRelease 2026-04-17T20:01:00+00:00 Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 https://ml.globenewswire.com/media/7e55cc25-f46f-423c-bf2a-e77ebaf69665/small/xilio-full-clr-logo-cmyk-png.png https://www.healthheraldgrenada.com/article/906376062-cardiff-oncology-presents-preclinical-data-on-its-plk1-inhibitor-onvansertib-in-combination-with-a-her2-targeted-adc-at-the-2026-aacr-annual-meeting Health Herald Grenada en PressRelease 2026-04-17T20:01:00+00:00 Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/916adb81-8173-4fbe-8095-c284c4f44cd3/small/cardiff-jpg.jpg https://www.healthheraldgrenada.com/article/906376104-olema-oncology-announces-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting Health Herald Grenada en PressRelease 2026-04-17T20:01:00+00:00 Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png https://www.healthheraldgrenada.com/article/906376473-nexgel-moves-forward-shareholder-update-call-to-discuss-celularity-transaction-on-april-21st-at-4-30-p-m-et Health Herald Grenada en PressRelease 2026-04-17T19:37:00+00:00 NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET https://ml.globenewswire.com/media/0e76fff8-7aee-4b60-ba26-62dda9975939/small/logo-png.png https://www.healthheraldgrenada.com/article/906351275-zentalis-pharmaceuticals-to-present-azenosertib-preclinical-data-in-triple-negative-breast-cancer-and-real-world-analysis-of-unmet-need-in-cyclin Health Herald Grenada en PressRelease 2026-04-17T19:15:00+00:00 Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 https://ml.globenewswire.com/media/1b481d6d-51c9-44f0-b33f-81feb1061d2e/small/zentalis-logo-png.png https://www.healthheraldgrenada.com/article/906350057-evaxion-s-ai-immunology-platform-demonstrates-86-vaccine-target-precision-in-phase-2-personalized-cancer-vaccine-trial Health Herald Grenada en PressRelease 2026-04-17T19:10:00+00:00 Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://www.healthheraldgrenada.com/article/906352123-surgery-partners-inc-announces-first-quarter-2026-earnings-release-date-and-conference-call-details Health Herald Grenada en PressRelease 2026-04-17T19:08:35+00:00 Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details https://ml.globenewswire.com/media/d0188456-e6d3-48f9-8479-b40422f00e4c/small/surgerypartnerslinear-1-jpg.jpg https://www.healthheraldgrenada.com/article/906352101-brazilian-wood-claims-evaluated-discover-the-male-enhancement-hardening-pill-truth-by-supernatural-man Health Herald Grenada en PressRelease 2026-04-17T19:07:25+00:00 Brazilian Wood Claims Evaluated: Discover the Male Enhancement Hardening Pill Truth by SuperNatural Man https://zingfast.com/wp-content/uploads/2026/04/Brazilian-Wood.jpg https://www.healthheraldgrenada.com/article/906349949-prame-directed-cell-therapy-using-immatics-tcr-induces-deep-and-durable-remission-in-pediatric-patient-with-advanced-metastatic-nephroblastoma Health Herald Grenada en PressRelease 2026-04-17T19:00:00+00:00 PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma https://ml-eu.globenewswire.com/media/1ef1cd0c-384c-4889-82c8-58bd42054fb8/small/immatics-final-logo-r-white-background-png.png https://www.healthheraldgrenada.com/article/906349959-asgard-therapeutics-to-present-preclinical-data-on-lead-asset-at-108-a-personalized-off-the-shelf-gene-therapy-at-aacr-annual-meeting-2026 Health Herald Grenada en PressRelease 2026-04-17T19:00:00+00:00 Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 https://ml-eu.globenewswire.com/media/5afbd1fa-9d4b-48d2-8f4f-d262d5a69053/small/asgard-tx-rgb-png.png https://www.healthheraldgrenada.com/article/906350035-new-data-demonstrates-the-unique-scalability-of-evaxion-s-ai-immunology-platform-in-glioblastoma Health Herald Grenada en PressRelease 2026-04-17T19:00:00+00:00 New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://www.healthheraldgrenada.com/article/906350165-pheast-therapeutics-reports-initial-phase-1a-data-showing-early-clinical-activity-and-target-engagement-for-phst001-at-aacr-2026 Health Herald Grenada en PressRelease 2026-04-17T19:00:00+00:00 Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026 https://ml.globenewswire.com/media/f27ab630-f23c-44f6-aae6-6fae240628af/small/pheast-logo-full-color-gradient-high-res-jpg.jpg https://www.healthheraldgrenada.com/article/906350188-zymeworks-presents-new-preclinical-data-at-aacr-2026-highlighting-broad-antibody-drug-conjugate-programs-including-novel-ras-targeting-platform Health Herald Grenada en PressRelease 2026-04-17T19:00:00+00:00 Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform https://ml.globenewswire.com/media/de376a45-7a16-49db-8ad4-65ff45472c90/small/zymeworks-logo-color-png.png https://www.healthheraldgrenada.com/article/906350191-biolojic-design-presents-new-preclinical-data-for-bd200-a-first-in-class-multibody-drug-conjugate-targeting-trop-2-and-nectin-4-at-the-american Health Herald Grenada en PressRelease 2026-04-17T19:00:00+00:00 Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting https://ml.globenewswire.com/media/5e7e1405-b691-484b-818b-1cb571d71d5c/small/biolojic-design-logo-vertical-color-resized-jpg.jpg https://www.healthheraldgrenada.com/article/906351284-mink-therapeutics-reports-phase-ii-data-on-immune-reprogramming-and-durable-survival-in-pd-1-refractory-gastroesophageal-cancer Health Herald Grenada en PressRelease 2026-04-17T19:00:00+00:00 MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer https://ml.globenewswire.com/media/6aa8e960-515a-40d6-9894-39ca47f5c84e/small/mink-logo-loyal-blue-and-light-blue-png.png https://www.healthheraldgrenada.com/article/906351536-jimstoppani-com-announces-summer-shred-challenge-with-25-000-grand-prize Health Herald Grenada en PressRelease 2026-04-17T18:40:00+00:00 JimStoppani.com Announces Summer Shred Challenge with $25,000 Grand Prize https://pressranger.s3.us-west-1.amazonaws.com/3232316/Screenshot-2026-04-17-at-9.07.35%E2%80%AFAM.png https://www.healthheraldgrenada.com/article/906350253-opticore-eye-group-unveils-new-contact-lens-program-in-riverside-ca-for-2026 Health Herald Grenada en PressRelease 2026-04-17T17:57:00+00:00 Opticore Eye Group Unveils New Contact Lens Program in Riverside, CA for 2026 https://pressranger.s3.us-west-1.amazonaws.com/3232295/OpticoreSquareLogo.png https://www.healthheraldgrenada.com/article/906351097-rebalancing-agents-hympavzi-pfizer-qfitlia-sanofi-alhemo-novo-nordisk-gain-ground-in-hemophilia-as-physicians-navigate-access-barriers-and Health Herald Grenada en PressRelease 2026-04-17T17:20:06+00:00 Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity https://ml.globenewswire.com/media/YjgxMGRkMDMtMDRjMC00ZTU5LTljMTUtODU4OTIyZTdlNzAxLTUwMDE1MTQyOC0yMDI2LTA0LTE3LWVu/tiny/Spherix-Global-Insights.png https://www.healthheraldgrenada.com/article/906351234-jellylean-claims-evaluated-discover-the-untold-truth-about-jelly-lean-gelatin-trick-gummies-recipe-for-weight-loss Health Herald Grenada en PressRelease 2026-04-17T17:12:39+00:00 JellyLean Claims Evaluated: Discover the Untold Truth About Jelly Lean Gelatin Trick Gummies Recipe for Weight Loss https://zingfast.com/wp-content/uploads/2026/04/JellyLean.jpg https://www.healthheraldgrenada.com/article/906351224-pacemakers-market-to-reach-7-5-billion-by-2030-driven-by-expanding-clinical-indications-and-aging-demographics Health Herald Grenada en PressRelease 2026-04-17T17:08:16+00:00 Pacemakers Market to Reach $7.5 Billion by 2030, Driven by Expanding Clinical Indications and Aging Demographics https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png